霉酚酸酯在C3肾小球病及疾病致病驱动因素中的作用
该回顾性多中心队列研究纳入97例C3肾小球病或致密沉积物病患者,分析糖皮质激素联合霉酚酸酯(MMF)的疗效。结果显示该方案与更高的缓解率和更低的肾衰竭概率相关,且疗效独立于补体异常或自身抗体等致病驱动因素,但补体基因致病性变异患者仅达部分缓解。
要点
- 糖皮质激素联合MMF治疗与更高的缓解率和更低的肾衰竭概率相关。
- 补体基因致病性变异患者仅达部分缓解,自身抗体介导者常见完全缓解。
- 基线蛋白尿是无缓解的主要决定因素,延长MMF疗程与较低复发风险相关。
核心结论
- 糖皮质激素联合MMF治疗C3肾小球病的获益反应似乎独立于本研究分析的致病驱动因素。
研究设计与样本
- 回顾性、多中心、观察性队列研究,纳入西班牙肾小球疾病研究组35个肾内科1995年1月至2018年3月诊断的C3肾小球病(n=81)或致密沉积物病(n=16)患者,共97例。
- 采用多变量分析和倾向评分匹配分析评估临床和遗传因素与治疗反应(缓解比例和无肾衰竭生存)的关联。
主要发现
- 糖皮质激素联合MMF治疗组缓解率为79%、肾衰竭概率为14%,优于其他免疫抑制剂组(24%和59%)、eculizumab组(33%和67%)及保守治疗组(18%和65%)。
- 糖皮质激素联合MMF的治疗优越性在补体异常和自身抗体患者中均可见。
- 补体基因致病性变异患者仅达部分缓解,而自身抗体介导形式常见完全缓解。
- 无缓解的主要决定因素是基线蛋白尿。
- 获得缓解后停药复发率为33%,较长MMF疗程与较低复发风险相关。
临床怎么用
- 对于C3肾小球病,可考虑糖皮质激素联合MMF治疗,但需注意补体基因致病性变异患者可能仅达部分缓解。
- 治疗决策时应评估基线蛋白尿水平,其是无缓解的主要决定因素。
- 达到缓解后延长MMF疗程可能降低复发风险。
局限性
- 回顾性观察性设计,可能存在选择偏倚和混杂因素。
- 样本量有限(97例),部分亚组分析可能效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure). RESULTS: The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse. CONCLUSIONS: The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study.
引用
- Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, et al. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol. 2020. PMID: 32816888. doi:10.2215/CJN.15241219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。